"ProSomnus delivered record revenues, significant revenue growth and strong organizational execution in the second quarter of 2023," said Len Liptak, Chief Executive Officer. "The rapidly increasing ...
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea ("OSA"), will report its strong second ...
Obstructive Sleep Apnea treatment provider ProSomnus Inc OSA reported Q2 revenues of $6.9 million, up 43% Y/Y and a sequential revenue increase of 19%, slightly beating the consensus of $6.4 million.
SAN FRANCISCO, Aug. 26, 2022 /PRNewswire/ -- ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today ...
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
Most of the patients mild-to-moderate patients were treated to an apnea-hypopnea index of fewer than 10 events per hour. After a minimum one-year follow-up period, 96% of patients continued using ...
PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the ...
Good day, and thank you for standing by. Welcome to the ProSomnus Q4 2023 Earnings Investors Update. At this time, all participants are in listen-only mode. Please be advised that today's conference ...
ProSomnus, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.42 EPS, expectations were $-0.31. OSA isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results